Arvinas (ARVN) Cash from Financing Activities (2017 - 2026)
Arvinas (ARVN) recorded quarterly Cash from Financing Activities of -$100000.0 in Q1 2026, up 99.86% quarter-over-quarter from -$74.0 million in Q4 2025, and little changed on a YoY basis from -$100000.0 in Q1 2025.
Arvinas (ARVN) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Arvinas' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$100000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed 0.0% year-over-year to -$100000.0; the TTM figure through Mar 2026 stood at -$91.4 million (down 1574.19% YoY), while the FY2025 annual figure was -$91.4 million, down 1256.96% from the prior year.
- Cash from Financing Activities was -$100000.0 for Q1 2026 at Arvinas, up from -$74.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $334.8 million in Q4 2023 to a low of -$74.0 million in Q4 2025.
- Historically, Cash from Financing Activities has averaged $17.4 million across 5 years, with a median of $500000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 66860.0% in 2023, then sank 14900.0% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $500000.0 in 2022, then soared by 66860.0% to $334.8 million in 2023, then slumped by 99.85% to $500000.0 in 2024, then tumbled by 14900.0% to -$74.0 million in 2025, then surged by 99.86% to -$100000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$100000.0 (Q1 2026), -$74.0 million (Q4 2025), and -$17.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | -74.00 Mn |
| Dec 31, 2025 | -74.00 Mn |
| Sep 30, 2025 | -17.80 Mn |
| Sep 30, 2025 | -17.80 Mn |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 334.80 Mn |
| Dec 31, 2023 | 334.80 Mn |